Literature DB >> 25023904

Could four-dimensional contrast-enhanced ultrasound replace computed tomography angiography during follow up of fenestrated endografts? Results of a preliminary experience.

M Gargiulo1, E Gallitto2, C Serra3, A Freyrie1, C Mascoli1, C Bianchini Massoni1, M De Matteis4, C De Molo1, A Stella1.   

Abstract

OBJECTIVE: To evaluate four-dimensional contrast-enhanced ultrasound (4D-CEUS) as an alternative imaging method to computed tomography angiography (CTA) during follow up of fenestrated endovascular aneurysm repair (FEVAR) for juxta- and para-renal abdominal aortic aneurysms (AAA).
METHODS: Between October 2011 and March 2012, all consecutive patients who underwent FEVAR follow up were included in the study and evaluated with both 4D-CEUS and CTA. The interval between the two examinations was always ≤ 30 days. Endpoints were the comparison of postoperative AAA diameter, AAA volume, presence of endoleaks, revascularized visceral vessel (RVV) visualization, and patency. Comparative analysis was performed using Bland-Altman plots and McNemar's Chi-square test.
RESULTS: Twenty-two patients (96% male, 4% female; mean age 74 ± 7 years; American Society of Anesthesiologists grade III/IV 82%/18%) were enrolled. Seventy-eight RVV (fenestrations: 60; scallops: 17; branches: 1) were analyzed. The mean AAA diameter evaluated by 4D-CEUS and CTA was 45 ± 10 mm (range 30-69 mm) and 48 ± 9 mm (range 32-70 mm), respectively. The mean difference was 3 ± 3 mm. The mean AAA volume evaluated by 4D-CEUS and CTA was 150 ± 7 cc (range 88-300 cc) and 159 ± 68 cc (range 80-310 cc), respectively. The mean difference was 7 ± 4 cc; a Bland-Altman plot revealed agreement in AAA diameter and volume evaluation (p < .01) between 4D-CEUS and CTA. The observed agreement for the detection of endoleaks was 95%. McNemar's Chi-square test confirmed that 4D-CEUS and CTA were equivalent (p > .05) at detecting endoleaks. The first segment of six (8%) RVVs (four renal and two superior mesenteric arteries) was not directly visualized by 4D-CEUS owing to obesity, but the contrast enhancement into the distal part of vessel or into the relative parenchyma gave indirect information about their patency. McNemar's Chi-square test demonstrated the superiority of CTA (p = .031) in visualizing RVVs. The patency of 77/78 RVVs was confirmed with both techniques. McNemar's Chi-square test confirmed that 4D-CEUS and CTA were equivalent in their ability to detect visceral vessel patency.
CONCLUSIONS: The data suggest that 4D-CEUS is as accurate as CTA in the evaluation of postoperative AAA diameter and volume, endoleak detection, and RVV patency after FEVAR. Four-dimensional CEUS could provide hemodynamic information regarding RVVs, and reduce radiation exposure and renal impairment during follow up. Obesity limits the diagnostic accuracy of 4D-CEUS.
Copyright © 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aortic aneurysm; Contrast-enhanced ultrasound; Fenestrated endograft; Follow up

Mesh:

Year:  2014        PMID: 25023904     DOI: 10.1016/j.ejvs.2014.05.025

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  13 in total

Review 1.  Contrast echocardiography: latest developments and clinical utility.

Authors:  Thomas R Porter; Feng Xie
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

Review 2.  Evolving clinical applications of contrast-enhanced ultrasound (CEUS) in the abdominal aorta.

Authors:  Vasileios Rafailidis; Sasan Partovi; Alexander Dikkes; Dean A Nakamoto; Nami Azar; Daniel Staub
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

Review 3.  Multimodality imaging assessment of endoleaks post-endovascular aortic repair.

Authors:  Sasan Partovi; Thomas Trischman; Vasileios Rafailidis; Suvranu Ganguli; Fabian Rengier; Harold Goerne; Prabhakar Rajiah; Daniel Staub; Indravadan J Patel; George Oliveira; Brian Ghoshhajra
Journal:  Br J Radiol       Date:  2018-05-02       Impact factor: 3.039

Review 4.  A Narrative Review on Contrast-Enhanced Ultrasound in Aortic Endograft Endoleak Surveillance.

Authors:  Sriharsha Gummadi; John R Eisenbrey; Andrej Lyshchik
Journal:  Ultrasound Q       Date:  2018-09       Impact factor: 1.657

5.  Intraoperative contrast enhanced ultrasound adds some important details to the endovascular aortic aneurysm repair completion control.

Authors:  Chiara Mascoli; Gianluca Faggioli; Enrico Gallitto; Rodolfo Pini; Mauro Gargiulo
Journal:  Ann Transl Med       Date:  2019-12

Review 6.  Ultrasonography for endoleak detection after endoluminal abdominal aortic aneurysm repair.

Authors:  Iosief Abraha; Maria Laura Luchetta; Rita De Florio; Francesco Cozzolino; Giovanni Casazza; Piergiorgio Duca; Basso Parente; Massimiliano Orso; Antonella Germani; Paolo Eusebi; Alessandro Montedori
Journal:  Cochrane Database Syst Rev       Date:  2017-06-09

Review 7.  Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials.

Authors:  Soufiane El Kadi; Thomas R Porter; Niels J W Verouden; Albert C van Rossum; Otto Kamp
Journal:  JACC Cardiovasc Imaging       Date:  2021-10-13

Review 8.  Vascular ultrasound, the potential of integration of multiparametric ultrasound into routine clinical practice.

Authors:  Vasileios Rafailidis; Paul S Sidhu
Journal:  Ultrasound       Date:  2018-02-28

Review 9.  Contemporary Applications of Ultrasound in Abdominal Aortic Aneurysm Management.

Authors:  Mark Scaife; Triantafillos Giannakopoulos; Georges E Al-Khoury; Rabih A Chaer; Efthymios D Avgerinos
Journal:  Front Surg       Date:  2016-05-27

10.  Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases.

Authors:  Ahmed El Kaffas; Rosa Maria Silveira Sigrist; George Fisher; Sunitha Bachawal; Joy Liau; Huaijun Wang; Alexander Karanany; Isabelle Durot; Jarrett Rosenberg; Dimitre Hristov; Jürgen K Willmann
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.